Abstracts tagged "Chondrogenesis"

Abstract Number: 0716 • ACR Convergence 2024
Outcomes of COVID-19 in Patients with ANCA-Associated Vasculitis (AAV)
Husam El Sharu¹, Teeba Mubaydeen² and Maria Romero Noboa³, ¹East Carolina University, Greenville, NC, ²King Hussein Cancer Center, Amman, Jordan, ³University of Alabama at Birmingham, Chicago, IL
Background/Purpose: Patients with AAVs are typically on immunosuppression medications that might increase their risk of severe infections. COVID-19 has been associated with severe pulmonary manifestations…
Abstract Number: 0859 • ACR Convergence 2023
Single Injection AAV2-hFGF18 Demonstrates Superior Safety and Efficacy over Repeat rhFGF18 Protein Injections in a Model of Induced Osteoarthritis
Alex Goraltchouk¹, Judith Hollander², Francesco Luppino³, Li Zeng² and Alexey Seregin³, ¹Remedium Bio, Inc, Needham, MA, ²Tufts University, Boston, MA, ³Remedium Bio, Inc., Needham, MA
Background/Purpose: Osteoarthritis (OA) is the largest unmet need in rheumatology, affecting 1 in 7 adults, with no approved disease modifying treatments. A recent placebo-controlled clinical…
Abstract Number: 1595 • ACR Convergence 2023
Pharmacological Modulation of Krüppel-like Factor 4 Reduces the Severity of Experimental Osteoarthritis via Tissue Protection and Regeneration
Manabu Kawata¹, Merissa Olmer², Kristen Johnson³ and Martin K Lotz², ¹Scripps Research Institute, San Diego, CA, ²Scripps Research Institute, La Jolla, CA, ³CALIBR, La Jolla, CA
Background/Purpose: Krüppel-like factors (KLFs) are members of the zinc finger family of transcription factors, which includes 17 members in mammals. We found that expression of…
Abstract Number: 0703 • ACR Convergence 2020
Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect
Francis Berenbaum¹, Coralie Meurot², Laure Sudre³, Keren Bismuth², Revital Rattenbach², Patrice Denefle², Celine Martin² and Claire Jacques³, ¹AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ²Campus Institut Pasteur Lille, 4P Pharma, Lille, France, ³Inserm, UMR_S938, Hospital Saint-Antoine, Paris, France
Background/Purpose: Osteoarthritis (OA) is an age-related joint disease affecting millions of individuals worldwide and associated with an extremely high burden largely attributable to disability. To…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].